The Combination of DPP-4 Inhibitors Versus Sulfonylureas with Metformin After Failure of First-line Treatment in the Risk for Major Cardiovascular Events and Death

Canadian Journal of Diabetes

Volumn 39, Issue 5, 2015, Pages 383-389

  Yu, Oriana Hoi Yun ^a,b   Yin, Hui ^a   Azoulay, Laurent ^a,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

All cause mortality; Cardiovascular outcomes; Pharmacoepidemiology; Type 2 diabetes treatment

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; METFORMIN; SULFONYLUREA DERIVATIVE; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; RISK REDUCTION; TREATMENT OUTCOME; UNITED KINGDOM; AGED; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK ASSESSMENT; STROKE;

AGED; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HUMANS; MALE; METFORMIN; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; STROKE; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME;

EID: 84943350333     PISSN: 14992671     EISSN: 23523840     Source Type: Journal    
DOI: 10.1016/j.jcjd.2015.02.002     Document Type: Article

References (35)

1. Bailey T. Options for Combination Therapy in Type 2 Diabetes: Comparison of the ADA/EASD Position Statement and AACE/ACE Algorithm. Am J Med 2013, 126(Suppl 1):S10-S20.
2. Inzucchi S.E., Bergenstal R.M., Buse J.B., et al. Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35:1364-1379.
3. Harper W., Goldenberg R., et al. Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: Pharmacologic management of type 2 diabetes. Can J Diabetes 2013, 37(Suppl 1):S61-S68.
4. (UKPDS) UKPDS. Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995, 310:83.
5. Group UKPDS. Overview of 6 years' therapy of type II diabetes: A progressive disease. Diabetes 1995, 44:1249.
6. Group UPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837.
7. Bianchi C., Miccoli R., Daniele G., et al. Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality?. Yes. Diabetes Care 2009, 32(Suppl 2):S342-S348.
8. Sehra D., Sehra S., Sehra S.T. Sulfonylureas: Do we need to introspect safety again?. Expert Opin Drug Saf 2011, 10:851-861.
9. Wheeler S., Moore K., Forsberg C.W., et al. Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy. Diabetologia 2013, 56:1934-1943.
10. Morgan C.L., Poole C.D., Evans M., et al. What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes. J Clin Endocrinol Metabol 2012, 97:4605-4612.
11. Jick H., Jick S.S., Derby L.E. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 1991, 302:766-768.
12. Khan N.F., Harrison S.E., Rose P.W. Validity of diagnostic coding within the General Practice Research Database: A systematic review. Brit J Gen Pract 2010, 60:e128-e136.
13. Burns E.M., Rigby E., Mamidanna R., et al. Systematic review of discharge coding accuracy. J Pub Health Med (Oxford) 2012, 34:138-148.
14. Roumie C.L., Hung A.M., Greevy R.A., et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: A cohort study. Ann Intern Med 2012, 157:601-610.
15. Azoulay L., Yin H., Filion K.B., et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: Nested case-control study. BMJ 2012, 344:e3645.
16. Morgan C.L., Mukherjee J., Jenkins-Jones S., et al. Association between first-line monotherapy with sulfonylurea versus metformin and risk of all-cause mortality and cardiovascular events: A retrospective, observational study. Diabetes, Obesity Metabol 2014, 16:957-962.
17. Berkowitz S.A., Krumme A.A., Avorn J., et al. Initial choice of oral glucose-lowering medication for diabetes mellitus: A patient-centered comparative effectiveness study. JAMA Intern Med 2014, 174:1955-1962.
18. Varas-Lorenzo C., Garcia-Rodriguez L.A., Perez-Gutthann S., Duque-Oliart A. Hormone replacement therapy and incidence of acute myocardial infarction: A population-based nested case-control study. Circulation 2000, 101:2572-2578.
19. Hammad T.A., McAdams M.A., Feight A., et al. Determining the predictive value of Read/OXMIS codes to identify incident acute myocardial infarction in the General Practice Research Database. Pharmacoepidemiol Drug Safety 2008, 17:1197-1201.
20. Van Staa T.P., Abenhaim L. The quality of information recorded on a UK database of primary care records: A study of hospitalizations due to hypogylcemia and other conditions. Pharmacoepidemiol Drug Safety 1994, 3:15-21.
21. Schneeweiss S., Rassen J.A., Glynn R.J., et al. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 2009, 20:512-522.
22. Rassen J.A., Glynn R.J., Brookhart M.A., Schneeweiss S. Covariate selection in high-dimensional propensity score analyses of treatment effects in small samples. Am J Epidemiol 2011, 173:1404-1413.
23. Morgan C.L., Mukherjee J., Jenkins-Jones S., et al. Combination therapy with metformin plus sulfonylureas versus metformin plus DPP-4 inhibitors: Association with major adverse cardiovascular events and all-cause mortality. Diabetes Obesity Metabol 2014, 16:977-983.
24. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 2008, 167:492-499.
25. Hirst J.A., Farmer A.J., Dyar A., et al. Estimating the effect of sulfonylurea on HbA1c in diabetes: A systematic review and meta-analysis. Diabetologia 2013, 56:973-984.
26. Karagiannis T., Paschos P., Paletas K., et al. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: Systematic review and meta-analysis. BMJ 2012, 344:e1369.
27. Hermansen K., Mortensen L.S. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Safety 2007, 30:1127-1142.
28. Goto A., Arah O.A., Goto M., et al. Severe hypoglycaemia and cardiovascular disease: Systematic review and meta-analysis with bias analysis. BMJ 2013, 347:f4533.
29. Kramer C.K., Zinman B., Retnakaran R. Are metabolically healthy overweight and obesity benign conditions? A systematic review and meta-analysis. Ann Intern Med 2013, 159:758-769.
30. Bowker S.L., Majumdar S.R., Veugelers P., Johnson J.A. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006, 29:254-258.
31. Kowall B., Rathmann W., Kostev K. Are sulfonylurea and insulin therapies associated with a larger risk of cancer than metformin therapy? A retrospective database analysis. Diabetes Care 2015, 38:59-65.
32. Johnson J.A., Majumdar S.R., Simpson S.H., Toth E.L. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002, 25:2244-2248.
33. Forst T., Hanefeld M., Jacob S., et al. Association of sulphonylurea treatment with all-cause and cardiovascular mortality: A systematic review and meta-analysis of observational studies. Diabetes Vasc Dis Res 2013, 10:302-314.
34. Leibovitz E., Gottlieb S., Goldenberg I., et al. Sitagliptin pretreatment in diabetes patients presenting with acute coronary syndrome: Results from the Acute Coronary Syndrome Israeli Survey (ACSIS). Cardiovasc Diabetol 2013, 12:53.
35. Scirica B.M., Bhatt D.L., Braunwald E., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013, 369:1317-1326.